Trilogy Capital Inc. Grows Holdings in Eli Lilly and Company $LLY

Key Points

• Trilogy Capital Inc. increased its stake in Eli Lilly and Company by 242.1% in the second quarter, bringing its total holdings to 4,187 shares valued at $3,264,000.
• CEO David A. Ricks purchased 1,632 shares at an average price of $644.77 per share, while insider trading activity included additional purchases from director Jamere Jackson.
• In its recent earnings report, Eli Lilly exceeded expectations with an EPS of $6.31 and revenue of $15.56 billion, marking a 37.6% increase compared to the previous year.

Trilogy Capital Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 242.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,187 shares of the company's stock after buying an additional 2,963 shares during the quarter. Trilogy Capital Inc.'s holdings in Eli Lilly and Company were worth $3,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its holdings in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the first quarter valued at $4,613,912,000. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC grew its holdings in shares of Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after purchasing an additional 773,947 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Stock Up 8.2%

NYSE LLY opened at $825.92 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a fifty day moving average of $733.71 and a two-hundred day moving average of $766.37. The firm has a market capitalization of $781.70 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.06 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.